Recovery From Anesthesia After Robotic Assisted Radical Cystectomy

Regina Elena Cancer Institute

Status and phase: Unknown; Phase 4

Conditions: Anesthesiology Management

Treatments: Drug: Neostigmine, Atropine; Drug: Sugammadex Injectable Product

Study type: Interventional

Funder types: Other

Identifiers

NCT03144453

CE/2288

Details and patient eligibility

About

Robot-assisted radical cystectomy (RARC) requires specific surgical conditions: steep Trendelenburg position, prolonged pneumoperitoneum, effective neuromuscular block until the final stages of surgery. The aim of this study was to evaluate the quality of awakening in two groups of patients undergoing different combinations of curarization/reversal.

Enrollment: 50 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• ASA (american society of anesthesiologists) score ≤ III
• Patients underwent robotic assisted cystectomy

Exclusion criteria

• Cerebrovascular disease
• BMI (body mass index) ≥ 30

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

50 participants in 2 patient groups

Sugammadex

Experimental group

Description:

The patients received sugammadex as neuromuscular blockade reversal

Treatment:

Drug: Sugammadex Injectable Product

Standard

Active Comparator group

Description:

The patients received neostigmine + atropine as neuromuscular blockade reversal

Treatment:

Drug: Neostigmine, Atropine